Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences, Inc. (IGMS) generates news primarily through its clinical-stage biotechnology activities and corporate transactions. The company has described itself as focused on developing engineered IgM-based therapeutic antibodies, including T cell engaging IgM antibodies, for cancer and autoimmune and inflammatory diseases. Its updates often cover progress in clinical trials, strategic shifts in its pipeline, collaboration developments and significant corporate events.
News items have detailed the advancement of key product candidates such as imvotamab, a CD20 x CD3 bispecific IgM T cell engager antibody studied in autoimmune indications including rheumatoid arthritis, systemic lupus erythematosus and idiopathic inflammatory myopathies, and IGM‑2644, a CD38 x CD3 T cell engager antibody in development for autoimmune diseases. Other releases have described clinical studies of aplitabart (also referred to as IGM‑8444), a death receptor 5 agonist evaluated in combination regimens for metastatic colorectal cancer, along with enrollment milestones and trial design features.
Corporate news has included a strategic pivot to focus exclusively on autoimmunity, with an associated pipeline transformation and workforce changes, followed by a later decision to halt further development of imvotamab and IGM‑2644 for autoimmune diseases and to explore internal options and strategic alternatives. IGM Biosciences has also issued announcements about its exclusive worldwide collaboration agreement with Sanofi on IgM antibody agonists for immunology and inflammation targets and other collaborations with biotechnology partners.
A major development in the company’s news flow is the announcement of a definitive merger agreement under which Concentra Biosciences, LLC will acquire IGM Biosciences through a cash tender offer and subsequent merger, with IGM Biosciences becoming a wholly owned subsidiary of Concentra. For readers following IGMS, the news stream provides context on the evolution of the company’s IgM antibody pipeline, its strategic decisions and the transaction that led to its acquisition.
IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, has announced that CEO Fred Schwarzer will speak at three major investor conferences in New York. The conferences include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, Baird 2022 Global Healthcare Conference on September 13, and H.C. Wainwright 24th Annual Global Investment Conference on September 14. Live webcasts will be available on the company's website, with replays archived for 90 days.
IGM Biosciences reported a net loss of $58.6 million, or $1.33 per share, for Q2 2022, compared to a $38.7 million loss in Q2 2021. The company received a $150 million upfront payment from Sanofi as part of a collaboration agreement to develop IgM antibodies. Cash and investments totaled $513.2 million at the end of Q2 2022. The firm continues advancing its clinical trials for imvotamab and IGM-8444, with initial safety updates expected soon. IGM anticipates filing IND applications for two new therapies this year and has projected 2022 cash reserves to be around $400 million.
IGM Biosciences, a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 3:00 p.m. EST in New York. The event will be available via live webcast, with a replay accessible for 90 days on the company’s website. IGM specializes in developing IgM antibodies, leveraging a proprietary technology platform to address manufacturing challenges and enhance therapeutic applications compared to IgG antibodies.
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology firm, announced that CEO Fred Schwarzer will partake in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:30 a.m. EST in New York. The event will be live-streamed on the Company’s website, with a replay available for 90 days. IGM Biosciences specializes in developing engineered IgM antibodies and has established a proprietary technology platform to enhance therapeutic use, overcoming previous manufacturing challenges since its inception in 2010.
IGM Biosciences has announced significant developments including a $150 million upfront payment from Sanofi as part of their exclusive global collaboration for researching IgM antibodies. The company also raised $230 million through a public equity offering. Clinical progress continues with IGM-2323 and IGM-8444, and the filing of IND applications for IGM-7354 and IGM-2644 is expected this year. Financials reveal a net loss of $51.9 million for Q1 2022, with operating expenses projected between $250 million and $260 million for the year.
IGM Biosciences Secures $150 Million from Sanofi
IGM Biosciences, Inc. (Nasdaq: IGMS) has successfully completed its collaboration agreement with Sanofi, with the $150 million upfront payment marking the commencement of the partnership. This collaboration focuses on developing IgM antibody agonists for three oncology and three immunology targets. The deal also includes potential milestone payments exceeding $6 billion, profit-sharing agreements, and royalties on global sales. CEO Fred Schwarzer expressed enthusiasm about the collaboration, emphasizing its potential to advance IGM's innovative IgM antibody platform.
IGM Biosciences (NASDAQ: IGMS) announced the closure of its public offering of 8,695,653 shares of non-voting common stock and an additional 1,304,347 shares of voting common stock after underwriters exercised their option. The offering price was $23.00 per share, generating approximately $230 million in gross proceeds before expenses. J.P. Morgan, BofA Securities, Stifel, and Guggenheim acted as joint book-running managers. This offering was registered under a Form S-3 with the SEC, providing investors with detailed information through the final prospectus supplement.
IGM Biosciences, Inc. (NASDAQ: IGMS) has priced its underwritten public offering of 8,695,653 shares of non-voting common stock at $23.00 per share, aiming to raise approximately $200 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 1,304,347 shares of voting common stock. The offering is set to close on or around April 1, 2022, pending customary conditions. J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are the joint book-running managers for this offering.
IGM Biosciences, Inc. (NASDAQ: IGMS) announced a proposed public offering of $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering is subject to market conditions and will be conducted through a registration statement with the SEC. J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are joint book-running managers for the offering. The company specializes in engineered IgM antibodies, aiming to overcome manufacturing challenges in the field.
IGM Biosciences announced a global collaboration with Sanofi targeting oncology, autoimmune, and inflammation areas. IGM will receive a $150 million upfront payment, with potential total milestones exceeding $6 billion. The partnership will leverage IGM's IgM antibody technology. The initiation of two Phase 2 studies for IGM-2323 in patients with DLBCL and FL was also announced. For 2021, IGM reported a net loss of $165.2 million, or $4.93 per share, while cash and investments were at $229.5 million. A conference call is scheduled for 8:00 a.m. ET today.